Korean J Intern Med.  2010 Jun;25(2):154-161. 10.3904/kjim.2010.25.2.154.

The Impact of Generic Clopidogrel Bisulfate on Platelet Inhibition in Patients with Coronary Artery Stents: Results of the ACCEL-GENERIC Study

Affiliations
  • 1Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea. goodoctor@naver.com
  • 2Department of Laboratory Medicine, Gyeongsang National University Hospital, Jinju, Korea.

Abstract

BACKGROUND/AIMS
In patients with coronary artery stents, the cost of clopidogrel has been cited as a factor in the premature discontinuation of therapy. Thus, the introduction of lower-cost generic clopidogrel may increase patient compliance. However, platelet inhibition by generic clopidogrel has not been compared to the original clopidogrel formulation in patients with coronary artery stents. METHODS: We prospectively enrolled 20 patients receiving chronic therapy with the original clopidogrel bisulfate (Plavix(R)). After assessing patient compliance with Plavix(R), maintenance therapy was switched to generic clopidogrel bisulfate (Plavitor(R)). Platelet reactivity was assessed at baseline and 30-day after the switch using conventional aggregometry and the VerifyNow P2Y12 assay. RESULTS: All patients completed maintenance therapy with Plavitor(R). Before and after switching therapy maximal (36.5 +/- 7.9% vs. 39.8 +/- 16.2%, p = 0.280) and late platelet aggregation (23.5 +/- 10.9% vs. 29.1 +/- 18.3%, p = 0.156) with 5 micromol/L adenosine diphosphate (ADP) stimulus did not differ. Likewise, 20 micromol/L ADP-induced platelet aggregation and P2Y12 reaction unit in patients on Plavitor(R) therapy was comparable to that in patients on Plavix(R) therapy. However, Bland-Altman analysis showed wide limits of agreement between measured platelet reactivity on Plavix(R) vs. Plavitor(R) therapies. CONCLUSIONS: Among patients on Plavix(R) maintenance therapy with coronary stents, replacement with Plavitor(R) shows a comparable inhibition of ADP-induced platelet aggregation. However, due to poor inter-therapy agreement, between two regimens, physicians may be cautious when introducing generic clopidogrel bisulfate.

Keyword

Clopidogrel; Drugs, generic; Blood platelets; Purinoceptor P2Y12

MeSH Terms

Aged
Angioplasty, Transluminal, Percutaneous Coronary
Combined Modality Therapy
Coronary Artery Disease/*drug therapy/therapy
*Drug-Eluting Stents
Drugs, Generic/*administration & dosage/adverse effects
Female
Follow-Up Studies
Humans
Male
Middle Aged
Patient Compliance
Platelet Aggregation/drug effects
Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
Prospective Studies
Receptors, Purinergic P2/metabolism
Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives
Full Text Links
  • KJIM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr